Aquestive Therapeutics (AQST) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to $43.9 million.
- Aquestive Therapeutics' Accumulated Depreciation & Amortization rose 124.78% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.9 million, marking a year-over-year increase of 124.78%. This contributed to the annual value of $43.5 million for FY2024, which is 143.88% up from last year.
- Latest data reveals that Aquestive Therapeutics reported Accumulated Depreciation & Amortization of $43.9 million as of Q3 2025, which was up 124.78% from $43.8 million recorded in Q2 2025.
- In the past 5 years, Aquestive Therapeutics' Accumulated Depreciation & Amortization registered a high of $43.9 million during Q3 2025, and its lowest value of $37.8 million during Q1 2021.
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $42.5 million (2023), whereas its average is $41.9 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first plummeted by 249.03% in 2021, then surged by 711.3% in 2022.
- Over the past 5 years, Aquestive Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $39.9 million in 2021, then increased by 5.28% to $42.0 million in 2022, then rose by 2.19% to $42.9 million in 2023, then rose by 1.44% to $43.5 million in 2024, then increased by 0.91% to $43.9 million in 2025.
- Its last three reported values are $43.9 million in Q3 2025, $43.8 million for Q2 2025, and $43.6 million during Q1 2025.